Gilead Invests Further in Arcellx, Extends Collaboration
By Colin Kellaher
Gilead Sciences is investing another $200 million in clinical-stage biotechnology company Arcellx as part of an expansion of the duo's collaboration to include lymphomas.
The companies on Wednesday said Gilead's Kite unit has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, and that they are expanding the scope of the collaboration launched late last year for Arcellx's CART-ddBCMA to include lymphomas.
Foster City, Calif., biopharmaceutical company Gilead, which last year made an initial equity investment of $100 million in Arcellx, will buy another 3.24 million share at $61.68 apiece, a 30% premium to Tuesday's closing price of $47.47 for the Gaithersburg, Md., company.
Arcellx said the investment, which will boost Gilead's stake to about 13%, will extend its cash runway into 2027.
Arcellx also will receive an upfront cash payment of $85 million at closing and will be eligible for potential milestone payments, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 06:43 ET (11:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks